Ikervis is a ciclosporin emulsion for the treatment of severe keratitis in adults with dry eye disease that has not...
Read moreDetailsCationorm (cationic nanoemulsion) is a new preservative-free, hydrating and lubricating emulsion which protects the eye surface, reducing the discomfort and...
Read moreDetailsNew eye drop formulations are making dry eye treatment more affordable and accessible, especially for more severe sufferers. But Australia...
Read moreDetailsPharmaceutical firm Seqirus has announced that its new therapy Ikervis is now available via the Pharmaceutical Benefits Scheme (PBS), making...
Read moreDetailsPharmaceutical company Seqirus has announced that preservative-free dry eye therapy Cationorm is now accessible via the Pharmaceutical Benefits Scheme (PBS)...
Read moreDetailsAustralasian drug company AFT Pharmaceuticals has announced results from a post-market study of licensed dry eye therapy NovaTears + Omega-3,...
Read moreDetailsTopcon Healthcare's latest instrument for eye health practices wanting to strengthen their myopia and dry eye services is now available...
Read moreDetailsASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3. The company has introduced...
Read moreDetailsIn the final instalment of Insight's five-part dry eye series, optometrist Ms Marilyn Stern reveals how low overheads and no...
Read moreDetailsIn Part 4 of Insight's dry eye series, Melcare Biomedical CEO Anthony Moloney reveals how his company's Australian-made product has...
Read moreDetails
Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited